|
|||||
|
|
Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma |
|
| Authors: | C.F. Hsu S.Y. Lin J.J. Peir J.W. Liao Y.C. Lin F.I. Chou |
| Affiliation: | aInstitute of Nuclear Engineering and Science, National Tsing Hua University, Taiwan, ROC;bNuclear Science and Technology Development Center, National Tsing Hua University, Taiwan, ROC;cGraduate Institute of Veterinary Pathobiology, National Chung Hsing University, Taiwan, ROC;dDepartment of Veterinary medicine, National Chung Hsing University, Taiwan, ROC |
| Abstract: | Osteosarcoma is a malignant tumor commonly found in human and animals. The ability of boric acid (BA) to accumulate in osteosarcoma due to the mechanism of the bone formation of cancer cells would make boron neutron capture therapy (BNCT) an alternative therapy for osteosarcoma. This study evaluated the feasibility of using BA as the boron drug for BNCT of bone cancer. The cytotoxicity of BA to L929 cells exceeded that of UMR-106 cells. With 25 μg 10B/mL medium of BA treatment, the boron concentration in UMR-106 cells was higher than that in L929 cells. The biodistribution and pharmacokinetics of BA in Sprague–Dawley (SD) rats were studied by administrating 25 mg 10B/kg body weight to SD rats. Blood boron level decreased rapidly within one hour after BA injection. Boron concentration in the long bone was 4–6 time higher than that of blood. Results of this study suggest that BA may be a potential drug for BNCT for osteosarcoma. |
| Keywords: | Osteosarcoma BNCT UMR-106 cell Boric acid |
| 本文献已被 ScienceDirect 等数据库收录！ | |